Literature DB >> 15004157

B cell receptors and complement receptors target the antigen to distinct intracellular compartments.

Laure A Perrin-Cocon1, Christian L Villiers, Jean Salamero, Françoise Gabert, Patrice N Marche.   

Abstract

The processing of exogenous Ags is an essential step for the generation of immunogenic peptides that will be presented to T cells. This processing relies on the efficient intracellular targeting of Ags, because it depends on the content of the compartments in which Ags are delivered in APCs. Opsonization of Ags by the complement component C3 strongly enhances their presentation by B cells and increases their immunogenicity in vivo. To investigate the role of C3 in the targeting of Ags, we compared the intracellular traffic of proteins internalized by complement receptor (CR) and B cell receptor (BCR) in B lymphocytes. Whereas both receptors are able to induce efficient Ag presentation, their intracellular pathways are different. CR ligand is delivered to compartments containing MHC class II molecules (MHC-II) but devoid of transferrin receptor and Lamp-2, whereas BCR rapidly targets its ligand toward Lamp-2-positive, late endosomal MHC-II-enriched compartments through intracellular vesicles containing transferrin receptor. CR and BCR are delivered to distinct endocytic pathways, and the kinetic evolution of the protein content of these pathways is very different. Both types of compartments contain MHC-II, but CR-targeted compartments receive less neosynthesized MHC-II than do BCR-targeted compartments. The targeting induced by CR toward compartments that are distinct from BCR-targeted compartments probably participates in C3 modulation of Ag presentation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15004157     DOI: 10.4049/jimmunol.172.6.3564

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens.

Authors:  L Jeannine Brady
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

2.  Analysis of complement deposition and processing on Chlamydia trachomatis.

Authors:  Mads Lausen; Mikkel Eggert Thomsen; Gunna Christiansen; Nichlas Karred; Allan Stensballe; Tue Bjerg Bennike; Svend Birkelund
Journal:  Med Microbiol Immunol       Date:  2020-11-18       Impact factor: 3.402

3.  Plasma proteome analysis reveals overlapping, yet distinct mechanisms of immune activation in chronic HCV and HIV infections.

Authors:  Daniela M Schlatzer; Julia M Sugalski; Yanwen Chen; Jill Barnholtz-Sloan; Perica Davitkov; Fred E Hazlett; Nicholas Funderburg; Benigno Rodriguez; Michael M Lederman; Scott F Sieg; Mark R Chance; Donald D Anthony
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

Review 4.  The role of humoral innate immunity in hepatitis C virus infection.

Authors:  Alexander W Tarr; Richard A Urbanowicz; Jonathan K Ball
Journal:  Viruses       Date:  2012-01-05       Impact factor: 5.048

5.  The actin-based motor protein myosin II regulates MHC class II trafficking and BCR-driven antigen presentation.

Authors:  Fulvia Vascotto; Danielle Lankar; Gabrielle Faure-André; Pablo Vargas; Jheimmy Diaz; Delphine Le Roux; Maria-Isabel Yuseff; Jean-Baptiste Sibarita; Marianne Boes; Graça Raposo; Evelyne Mougneau; Nicolas Glaichenhaus; Christian Bonnerot; Bénédicte Manoury; Ana-Maria Lennon-Duménil
Journal:  J Cell Biol       Date:  2007-03-26       Impact factor: 10.539

Review 6.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

7.  High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate.

Authors:  Gladys S Ingle; Pamela Chan; J Michael Elliott; Wesley S Chang; Hartmut Koeppen; Jean-Philippe Stephan; Suzie J Scales
Journal:  Br J Haematol       Date:  2007-11-07       Impact factor: 6.998

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.